English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [2091]
News [6483]
Articles [133]
Editorials [5]
Conferences [171]
elearning [10]
Combining imaging and gene analysis could transform breast cancer diagnosis
Combining imaging and gene analysis could transform breast cancer diagnosis
Scientists identify genetic signatures for aggressive form of prostate cancer
Scientists identify genetic signatures for aggressive form of prostate cancer
Protein levels could predict if bowel cancer patients will benefit from bevacizumab
Protein levels could predict if bowel cancer patients will benefit from bevacizumab
Proteins in DNA damage response network targeted for new therapies
Proteins in DNA damage response network targeted for new therapies
Skin rash predicts survival benefit from latest lung cancer drug
Skin rash predicts survival benefit from latest lung cancer drug
Novel blood-based protein signature determined for rare, aggressive lung cancer
Novel blood-based protein signature determined for rare, aggressive lung cancer
Defects in epithelial barriers drive colorectal cancer growth
Defects in epithelial barriers drive colorectal cancer growth
ESMO 2012: First large scale trial of whole-genome cancer testing for clinical decision-making
ESMO 2012: First large scale trial of whole-genome cancer testing for clinical decision-making
Noninvasive measurement enables use of interstitial fluid pressure as potential biomarker for tumour aggressiveness
Noninvasive measurement enables use of interstitial fluid pressure as potential biomarker for tumour aggressiveness
ESMO 2012: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial
ESMO 2012: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III...
<1...628629630631632...649>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top